A Bristol Meyers Squibb executive was indicted for making a secret deal with a Canadian drug manufacturer that they wouldn’t make a generic version of Apotex, a competing drug to Plavix, if the Canucks didn’t make a generic version of Plavix. Under federal law, such anti-competitive agreements need to be submitted to the FTC. [NYT]